Annual Report

Overview

The report presents Orion Infusion Limited's FY2023-24 performance, including net revenue of BDT 827.42 million and net profit of BDT 42.33 million. It highlights production of 10.37 million intravenous fluids and injections against 10.98 million capacity. The company reports 718 employees and emphasizes GMP-based manufacturing, employee training and occupational safety. It also describes its contribution to dengue response through production and supply of essential IV fluids.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023-2024
Period: 1 July 2023 – 30 June 2024
Publication date: 13 November 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services